Absence seizure

From Wikipedia, the free encyclopedia - View original article

Absence seizure
Classification and external resources
Jump to: navigation, search
Absence seizure
Classification and external resources

Absence seizures are one of several kinds of seizures. These seizures are sometimes referred to as petit mal seizures (from the French for "little illness", a term dating from the late 18th century[1]).

Absence seizures are brief (usually less than 20 seconds), generalized epileptic seizures of sudden onset and termination. When someone experiences an absence seizure they are often unaware of their episode.[2] Those most susceptible to this are children and the first episode usually occurs between 4–12 years old. It is very rare that someone older will experience their first absence seizure.[citation needed] Episodes of absence seizures can often be mistaken for inattentiveness when misdiagnosed and can occur 50-100 times a day. They can be so difficult to detect that some people may go months or years before given a proper diagnosis. There are no known before or after effects of absence seizures.[3] They have two essential components:[4][5][6]

Absence seizures are broadly divided into typical and atypical types. Typical absence seizures usually occur in the context of idiopathic generalised epilepsies and EEG shows fast >2.5 Hz generalised spike-wave discharges. The prefix “typical” is to differentiate them from atypical absences rather than to characterise them as "classical" or characteristic of any particular syndrome.

Atypical absence seizures:

Signs and symptoms[edit]

The clinical manifestations of absence seizures vary significantly between patients.[4][5][6] Impairment of consciousness is the essential ictal element and may be the only clinical symptom, but this is often combined with other manifestations. The hallmark of the absence seizures is abrupt and sudden-onset impairment of consciousness, interruption of ongoing activities, a blank stare, possibly a brief upward rotation of the eyes. If the patient is speaking, speech is slowed or interrupted, if walking, he or she stands transfixed; if eating, the food will stop on its way to the mouth. Usually, the patient will be unresponsive when addressed. In some cases, attacks are aborted when the patient is called. The attack lasts from a few seconds to half a minute, and evaporates as rapidly as it commenced.

  1. Absence with impairment of consciousness only as per the above description
  2. Absence with mild clonic components. Here the onset of the attack is indistinguishable from the above, but clonic components may occur in the eyelids, at the corner of the mouth, or in other muscle groups which may vary in severity from almost imperceptible movements to generalised myoclonic jerks. Objects held in the hand may be dropped.
  3. Absence with atonic components. Here there may be a diminution in tone of muscles subserving posture as well as in the limbs leading to drooping of the head, occasionally slumping of the trunk, dropping of the arms, and relaxation of the grip. Rarely tone is sufficiently diminished to cause this person to fall.
  4. Absence with tonic components. Here during the attack tonic muscular contraction may occur, leading to increase in muscle tone which may affect the extensor muscles or the flexor muscles symmetrically or asymmetrically. If the patient is standing the head may be drawn backward and the trunk may arch. This may lead to retropulsion. The head may tonically draw to one or another side.
  5. Absence with automatisms. Purposeful or quasipurposeful movements occurring in the absence of awareness during an absence attack are frequent and may range from lip licking and swallowing to clothes fumbling or aimless walking. If spoken to the patient may grunt or to the spoken voice and when touched or tickled may rub the site. Automatisms are quite elaborate and may consist of combinations of the above described movements or may be so simple as to be missed by casual observation.
  6. Absence with autonomic components. These may be pallor and less frequently flushing, sweating, dilatation of pupils and incontinence of urine.

Mixed forms of absence frequently occur. These seizures can happen a few times a day or in some cases hundreds of times a day, to the point that the person cannot concentrate in school or other situations requiring sustained, concentrated attention.

Precipitating factors[edit]

Typical absences are easily induced by hyperventilation in more than 90% of the patients. This is a reliable test for the diagnosis of absence seizures: a patient suspected of typical absences should be asked to overbreathe for 3 min, counting his or her breaths. Intermittent photic stimulation may precipitate or facilitate absence seizures; eyelid myoclonia is a common clinical feature.


The only diagnostic test for absence seizures is EEG.[7] However, brain scans such as by an MRI can help rule out other diseases, such as a stroke or a brain tumor.[8]

During electroencephalography, hyperventilation can be used to provoke these seizures.[7] Ambulatory EEG monitoring over 24 hours can quantify the number of seizures per day and their most likely times of occurrence.[7]


These are childhood absence epilepsy, epilepsy with myoclonic absences and juvenile myoclonic epilepsy. Other proposed syndromes are Jeavons syndrome (eyelid myoclonia with absences) and genetic generalised epilepsy with phantom absencesPrecipitating factors of absence seizures.

These types of seizures are also known to occur to patients suffering with porphyria and can be triggered by stress or other porphrin-inducing factors.


Treatment of patients with absence seizures only is mainly with sodium valproate or ethosuximide, which are of equal efficacy controlling absences in around 75% of patients. Lamotrigine monotherapy is less effective, with nearly half of the patients becoming seizure free. This view has been recently confirmed by Glauser et al. (2010),[9] who performed a double-blind, randomized, controlled clinical trial to compare the efficacy, tolerability, and neuropsychological effects of ethosuximide, valproic acid, and lamotrigine in children with newly diagnosed childhood absence epilepsy. Drug dosages were incrementally increased until the child was free of seizures, the maximal allowable or highest tolerable dosage was reached, or a criterion indicating treatment failure was met. The primary outcome was freedom from treatment failure after 16 weeks of therapy; the secondary outcome was attentional dysfunction. Differential drug effects were determined by means of pairwise comparisons. The 453 children who were randomly assigned to treatment with ethosuximide (156), lamotrigine (149), or valproic acid (148) were similar with respect to their demographic characteristics. After 16 weeks of therapy, the freedom-from-failure rates for ethosuximide and valproic acid were similar (53% and 58%, respectively; odds ratio with valproic acid vs. ethosuximide, 1.26; 95% confidence interval [CI], 0.80 to 1.98; P = .35) and were higher than the rate for lamotrigine (29%; odds ratio with ethosuximide vs. lamotrigine, 2.66; 95% CI, 1.65 to 4.28; odds ratio with valproic acid vs. lamotrigine, 3.34; 95% CI, 2.06 to 5.42; P < .001 for both comparisons). There were no significant differences between the three drugs with regard to discontinuation because of adverse events. Attentional dysfunction was more common with valproic acid than with ethosuximide (in 49% of the children vs. 33%; odds ratio, 1.95; 95% CI, 1.12 to 3.41; P = .03). If monotherapy fails or unacceptable adverse reactions appear, replacement of one by another of the three antiepileptic drugs is the alternative. Adding small doses of lamotrigine to sodium valproate may be the best combination in resistant cases.

Although ethosuximide is often effective in treating absence seizures, valproate is much more effective in treating tonic-clonic seizure, and so it may be a better choice if a patient is exhibiting both types of seizures.[10] Clonazepam (Klonopin, Rivotril) is effective in the short term but is not generally recommended for treatment of absence seizure because of the rapid development of tolerance and high frequency of side effects.[11]

Contraindicated drugs[edit]

The treatment of idiopathic generalized epilepsy is demanding because many antiepileptic drugs are ineffective or exaggerate absences and myoclonic jerks. An antiepileptic drug is contraindicated not only when it exaggerates seizures but also when it is ineffective in controlling the seizures that it is supposed to treat. It may cause unnecessary adverse reactions and deprives the patient of the therapeutic effect that could be provided by another antiepileptic drug. Carbamazepine, vigabatrin, and tiagabine are contraindicated in the treatment of absence seizures, irrespective of cause and severity. This is based on clinical and experimental evidence.[6] In particular, the GABA agonists vigabatrin and tiagabine are used to induce, not to treat, absence seizures and absence status epilepticus. Similarly, phenytoin, phenobarbital, gabapentin, and pregabalin should not be used in the treatment of absence seizures.

Data limitations[edit]

In the treatment of absence seizures there is often insufficient evidence for which of the available medications has the best combination of safety and efficacy for a particular patient.[12] Nor is it easily known how long a medication must be continued before an off-medication trial should be conducted to determine whether the patient has outgrown the absence seizures, as is often the case in children. To date there have been no published results of any large, double-blind, placebo-controlled studies comparing the efficacy and safety of these or any other medications for absence seizures.[citation needed] The studies that exist have been small and not produced clear conclusions.[12][13]


  1. ^ Daly, D. D. (1968). "Reflections on the Concept of Petit Mal". Epilepsia 9 (3): 175–8. doi:10.1111/j.1528-1157.1968.tb04618.x. PMID 4975023. 
  2. ^ Carlson, Neil R. (2013). Physiology of Behavior. 
  3. ^ Epilepsy Therapy Project. "Absence Seizures". Epilepsy Foundation. Retrieved 8 May 2013. 
  4. ^ a b "Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy". Epilepsia 22 (4): 489–501. 1981. doi:10.1111/j.1528-1157.1981.tb06159.x. PMID 6790275. 
  5. ^ a b Panayiotopoulos, Chrysostomos P. (2008). "Typical absence seizures and related epileptic syndromes: Assessment of current state and directions for future research". Epilepsia 49 (12): 2131–9. doi:10.1111/j.1528-1167.2008.01777.x. PMID 19049569. 
  6. ^ a b c Panayiotopoulos, C. P. (2010). A clinical guide to epileptic syndromes and their treatment (2nd ed.). London: Springer. [page needed]
  7. ^ a b c Medscape > Absence Seizures by Scott Segan. Updated: Apr 27, 2011
  8. ^ Mayo Clinic > Absence seizure (petit mal seizure) June 23, 2011
  9. ^ Glauser, Tracy A.; Cnaan, Avital; Shinnar, Shlomo; Hirtz, Deborah G.; Dlugos, Dennis; Masur, David; Clark, Peggy O.; Capparelli, Edmund V.; Adamson, Peter C. (2010). "Ethosuximide, Valproic Acid, and Lamotrigine in Childhood Absence Epilepsy". New England Journal of Medicine 362 (9): 790–9. doi:10.1056/NEJMoa0902014. PMC 2924476. PMID 20200383. Lay summaryScienceDaily (March 12, 2010). 
  10. ^ Kahan, Scott; Brillman, Jon (2005). In A Page Neurology. Hagerstwon, MD: Lippincott Williams & Wilkins. p. 47. ISBN 978-1-4051-0432-6. 
  11. ^ Dreifuss, FE (1983). "Treatment of the nonconvulsive epilepsies". Epilepsia. 24 Suppl 1: S45–54. PMID 6413201. 
  12. ^ a b Posner, Ewa B; Mohamed, Khalid K; Marson, Anthony G (2005). "Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents". In Posner, Ewa B. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD003032.pub2. 
  13. ^ Posner, Ewa B.; Mohamed, Khalid; Marson, Anthony G. (2005). "A systematic review of treatment of typical absence seizures in children and adolescents with ethosuximide, sodium valproate or lamotrigine". Seizure 14 (2): 117–22. doi:10.1016/j.seizure.2004.12.003. PMID 15694565. 

External links[edit]